GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Forward PE Ratio

Ludwig Enterprises (Ludwig Enterprises) Forward PE Ratio : 0.00 (As of Jun. 19, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Forward PE Ratio?

Ludwig Enterprises's Forward PE Ratio for today is 0.00.

Ludwig Enterprises's PE Ratio without NRI for today is 0.00.

Ludwig Enterprises's PE Ratio for today is 0.00.


Ludwig Enterprises Forward PE Ratio Historical Data

The historical data trend for Ludwig Enterprises's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Forward PE Ratio Chart

Ludwig Enterprises Annual Data
Trend
Forward PE Ratio

Ludwig Enterprises Quarterly Data
Forward PE Ratio

Competitive Comparison of Ludwig Enterprises's Forward PE Ratio

For the Medical Devices subindustry, Ludwig Enterprises's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ludwig Enterprises's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ludwig Enterprises's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Ludwig Enterprises's Forward PE Ratio falls into.



Ludwig Enterprises Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Ludwig Enterprises  (OTCPK:LUDG) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Ludwig Enterprises Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ludwig Enterprises (Ludwig Enterprises) Business Description

Traded in Other Exchanges
N/A
Address
1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.